STANDARD BIOTOOLS INC.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
LAB$0.64+2.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $129,418 | $166,728 |
| Short-term investments | 65,485 | 126,146 |
| Accounts receivable, net | 13,536 | 14,741 |
| Inventory | 25,418 | 20,744 |
| Prepaid expenses and other current assets | 7,906 | 4,561 |
| Current assets held for sale | 230,676 | 42,963 |
| Total current assets | 472,439 | 375,883 |
| Property and equipment, net | 20,738 | 22,775 |
| Operating lease right-of-use asset, net | 23,453 | 26,567 |
| Other non-current assets | 3,521 | 3,688 |
| Long-term investments | 19,485 | — |
| Non-current assets held for sale | — | 183,432 |
| Total assets | $539,636 | $612,345 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,619 | $5,049 |
| Accrued liabilities | 30,810 | 21,435 |
| Operating lease liabilities, current | 5,113 | 4,806 |
| Deferred revenue, current | 40,111 | 10,274 |
| Deferred grant income, current | 3,098 | 3,527 |
| Current liabilities held for sale | 22,214 | 20,804 |
| Total current liabilities | 107,965 | 65,895 |
| Convertible notes, non-current | 299 | 299 |
| Deferred tax liability | 1,139 | 1,081 |
| Operating lease liabilities, non-current | 21,977 | 25,590 |
| Deferred revenue, non-current | 2,366 | 32,674 |
| Deferred grant income, non-current | 5,031 | 7,243 |
| Other non-current liabilities | 1,200 | 1,062 |
| Non-current liabilities held for sale | — | 6,779 |
| Total liabilities | 139,977 | 140,623 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value, 10,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock: $0.001 par value, 600,000 shares authorized at September 30, 2025 and December 31, 2024; 402,194 and 396,110 shares issued at September 30, 2025 and December 31, 2024, respectively; 383,614 and 377,530 shares outstanding at September 30, 2025 and December 31, 2024, respectively | 401 | 396 |
| Additional paid-in capital | 1,726,032 | 1,702,219 |
| Accumulated other comprehensive loss | (477) | 1,225 |
| Accumulated deficit | (1,279,830) | (1,185,651) |
| Treasury stock at cost: 18,580 shares at September 30, 2025 and December 31, 2024 | (46,467) | (46,467) |
| Total stockholders’ equity | 399,659 | 471,722 |
| Total liabilities and stockholders’ equity | $539,636 | $612,345 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.